Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer.
10.3881/j.issn.1000-503X.11968
- Author:
Heng Yi CHEN
1
;
Yong HE
1
Author Information
1. Department of Respiratory and Critical Care Medicine,Daping Hospital,Army Medical University of the People's Liberation Army,Chongqing 400042,China.
- Publication Type:Journal Article
- Keywords:
hepatocyte growth factor;
mesenchymal-epithelial transition factor;
non-small cell lung cancer;
resistance to targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
Epithelial-Mesenchymal Transition;
Hepatocyte Growth Factor;
Humans;
Lung Neoplasms/genetics*;
Proto-Oncogene Proteins c-met/metabolism*;
Signal Transduction
- From:
Acta Academiae Medicinae Sinicae
2021;43(2):259-264
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy is an important therapeutic method for advanced non-small cell lung cancer with driver gene alteration.However,resistance to targeted therapy will inevitably happen in clinical practice,which has become a major issue demanding prompt solution.Studies have demonstrated that bypass resistance mediated by the activation of hepatocyte growth factor(HGF)/mesenchymal-epithelial transition factor(MET)signaling pathway is a common cause of resistance to targeted therapy.Presently,relevant studies have accumulated rich experience in the specific mechanisms.To be brief,HGF/MET is an important target for overcoming the resistance to targeted therapy and promises to be a leading biomarker for judging and observing the occurrence of resistance.This paper introduces the recent studies concerning the effects and mechanisms of HGF/MET signaling pathway on resistance to targeted therapy.
